Disease biology centered approach to drug repurposing. Disease biology and pathways have been evolutionarily conserved as such for a reason. We try to look through these reasons and find ways to treat the disease phenotype.
Targeted therapies have been successfully developed in recent decades. These clinical stage assets constitute a toolbox for future combination therapies that would significantly improve upon existing treatments.
MGC001 for Urinary Hesitancy
Trouble peeing can involve difficulties in starting or maintaining the stream. An enlarged prostate in men is by far the most common cause (benign prostatic hyperplasia). Prostate is the male anatomical equivalence to the female uterus that grows throughout lifetime under the influence of androgens.
Symptoms develop gradually without pain. People get used to having a weak stream and tend to avoid talking about it or seeking medical advice. Antiandrogens can be prescribed to shrink the prostate; or PDE5 inhibitors to relax the muscles in the urethra. However, continuous daily medication is required to maintain efficacy.
MGC001 is a once weekly oral pill that effectively suppresses prostatic hyperplasia and keeps urine flowing for men.
Excess scalp sebum
MGC003 for Androgenetic Alopecia
Hair loss affects millions of men and women, impacting appearance, social interactions, and psycho-emotional well-being. Androgenetic alopecia accounts for the majority of the hairloss.
MGC003 is an all oral combination therapy that vastly improves on existing treatment options.